U.S.-listed shares of Dutch drugmaker UniQure (UQ1.F) , (QURE.O) rise 61% to $22.95 in extended trading
The head of the U.S. Food and Drug Administration’s vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the end of April, FDA commissioner Marty Makary said on Friday
More recently, Prasad’s division at the FDA has been mired in a back and forth with Dutch drugmaker UniQure over its gene therapy for Huntington’s disease
Co is developing a gene therapy, AMT-130, for Huntington’s disease, a rare condition that affects motor function
Makary says in a post on X that a successor will be named before Prasad’s departure
Shares of some gene therapy developers also rose in extended trading, following the announcement
Shares of Sarepta Therapeutics (SRPT.O) rises 6%, Capricor Therapeutics (CAPR.O) climbs 12%, Taysha Gene Therapies (TSHA.O) gains 1%
UniQure rose 35.5% in 2025

SRPU

Reuters

iShares Global Healthcare

Tradr 2X Long SRPT Daily ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

VG Health

Sarepta Therap

iShares US Pharma

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Taysha Gene Therapies

Ark Genomic Revolution ETF

Capricor Therap

Uniqure

BUZZ-Uniqure jumps after FDA vaccines chief Vinay Prasad to step down